Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Japanese Journal of Ophthalmology
Published in: Japanese Journal of Ophthalmology 6/2015

01-11-2015 | Clinical Investigation

Diquafosol sodium ophthalmic solution for the treatment of dry eye: clinical evaluation and biochemical analysis of tear composition

Authors: Chika Shigeyasu, Masakazu Yamada, Yoko Akune, Kazuo Tsubota

Published in: Japanese Journal of Ophthalmology | Issue 6/2015

Login to get access

Abstract

Purpose

To evaluate the clinical efficacy of 3 % diquafosol sodium ophthalmic solution for dry eye, and to analyze the concentration of tear proteins and mucin-like substances after the treatment.

Methods

Fifty eyes of 25 patients with dry eye syndrome were prospectively enrolled. The patients were treated with diquafosol solution at a dose of 1 drop in each eye 6 times daily for 4 weeks. The parameters of clinical efficacy were tear osmolarity, tear breakup time (BUT), fluorescein staining scores for the cornea and conjunctiva, Schirmer test values, and subjective symptoms evaluated using the ocular surface disease index (OSDI). Tears collected with Schirmer test strips were analyzed by high-performance liquid chromatography, and the concentrations of the total protein and the 4 major tear proteins, namely, secretory IgA, lactoferrin, lipocalin-1, lysozyme, and N-acetyl-neuraminic acid (Neu5Ac), were measured. Neu5Ac is a major sialic acid, a marker of secretory mucins.

Results

The BUT, keratoconjunctival staining scores, and Schirmer test values were improved with statistical significance after the treatment with diquafosol solution, while changes in the other parameters, including tear osmolarity, corneal staining scores, and OSDI scores were not significant. The Neu5Ac concentration was significantly increased, which was not accompanied by changes in tear proteins.

Conclusions

Topical application of diquafosol significantly improved the clinical parameters of the BUT, keratoconjunctival staining scores, and Schirmer test values and was accompanied by increased sialic acid content in the tears of patients with dry eye.
Literature
1.
Pflugfelder SC, Geerling G, Kinoshita S, Lemo MA, McCulley J, Nelson D, et al. Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye Workshop (2007). Ocul Surf. 2007;5:163–78.CrossRef
2.
Nichols KK, Yerxa B, Kellerman DJ. Diquafosol tetrasodium: a novel dry eye therapy. Expert Opin Investig Drugs. 2004;13:47–54.CrossRefPubMed
3.
Cowlen MS, Zhang VZ, Warnock L, Moyer CF, Peterson WM, Yerxa BR. Localization of ocular P2Y2 receptor gene expression by in situ hybridization. Exp Eye Res. 2003;77:77–84.CrossRefPubMed
4.
Murakami T, Fujihara T, Horibe Y, Nakamura M. Diquafosol elicits increases in net Cl-transport through P2Y2 receptor stimulation in rabbit conjunctiva. Ophthalmic Res. 2004;36:89–93.CrossRefPubMed
5.
Takaoka-Shichijyou Y, Murakami T, Nakamura M. Stimulatory effect of diquafosol tetrasodium on tear fluid secretion in normal rabbits [in Japanese]. Atarashii Ganka. 2011;28:1029–33.
6.
Jumblatt JE, Jumblatt MM. Regulation of ocular mucin secretion by P2Y2 nucleotide receptors in rabbit and human conjunctiva. Exp Eye Res. 1998;67:341–6.CrossRefPubMed
7.
Fujihara T, Murakami T, Nagano T, Nakamura M, Nakata K. INS365 suppresses loss of corneal epithelial integrity by secretion of mucin-like glycoprotein in a rabbit short-term dry eye model. J Ocul Pharmacol Ther. 2002;18:363–70.CrossRefPubMed
8.
Nakamura M, Imanaka T, Sakamoto A. Diquafosol ophthalmic solution for dry eye treatment. Adv Ther. 2012;29:579–89.CrossRefPubMed
9.
Takamura E, Tsubota K, Watanabe H, Ohashi Y. A randomised, double-masked comparison study of diquafosol versus sodium hyaluronate ophthalmic solutions in dry eye patients. Br J Ophthalmol. 2012;96:1310–5.PubMedCentralCrossRefPubMed
10.
Matsumoto Y, Ohashi Y, Watanabe H, Tsubota K. Efficacy and safety of diquafosol ophthalmic solution in patients with dry eye syndrome: a Japanese phase 2 clinical trial. Ophthalmology. 2012;119:1954–60.CrossRefPubMed
11.
Tauber J, Davitt WF, Bokosky JE, Nichols KK, Yerxa BR, Schaberg AE, et al. Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye. Cornea. 2004;23:784–92.CrossRefPubMed
12.
Koh S, Maeda N, Ikeda C, Oie Y, Soma T, Tsujikawa M, et al. Effect of diquafosol ophthalmic solution on the optical quality of the eyes in patients with aqueous-deficient dry eye. Acta Ophthalmol. 2014;92:e671–5.CrossRefPubMed
13.
Arita R, Suehiro J, Haraguchi T, Maeda S, Maeda K, Tokoro H, et al. Topical diquafosol for patients with obstructive meibomian gland dysfunction. Br J Ophthalmol. 2013;97:725–9.PubMedCentralCrossRefPubMed
14.
Yokoi N, Kato H, Kinoshita S. Facilitation of tear fluid secretion by 3% diquafosol ophthalmic solution in normal human eyes. Am J Ophthalmol. 2014;157:85–92.CrossRefPubMed
15.
16.
Hwang HS, Sung YM, Lee WS, Kim EC. Additive effect of preservative-free sodium hyaluronate 0.1% in treatment of dry eye syndrome with diquafosol 3% eye drops. Cornea. 2014;33:935–41.CrossRefPubMed
17.
Shimazaki J, Tsubota K, Kinoshita S, Ohashi Y, Shimomura Y, Tagawa Y, et al. Definition and diagnosis of dry eye 2006 [in Japanese]. Atarashii Ganka. 2007;24:181–4.
18.
Lemp MA, Baudouin C, Baum J, Dogru M, Foulks GN, Kinoshita S, et al. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye Workshop (2007). Ocul Surf. 2007;5:75–92.CrossRef
19.
Shimmura S, Ono M, Shinozaki K, Toda I, Takamura E, Mashima Y, et al. Sodium hyaluronate eyedrops in the treatment of dry eyes. Br J Ophthalmol. 1995;79:1007–11.PubMedCentralCrossRefPubMed
20.
Koh S, Watanabe H, Hosohata J, Hori Y, Hibino S, Nishida K, et al. Diagnosing dry eye using a blue-free barrier filter. Am J Ophthalmol. 2003;136:513–9.CrossRefPubMed
21.
22.
Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. Reliability and validity of the ocular surface disease index. Arch Ophthalmol. 2000;118:615–21.CrossRefPubMed
23.
Yamada M, Mochizuki H, Kawai M, Tsubota K, Bryce TJ. Decreased tear lipocalin concentration in patients with meibomian gland dysfunction. Br J Ophthalmol. 2005;89:803–5.PubMedCentralCrossRefPubMed
24.
Shigeyasu C, Hirano S, Akune Y, Mochizuki H, Yamada M. Evaluation of the frequency of ophthalmic solution application: washout effects of topical saline application on tear components. Curr Eye Res. 2013;38:722–8.CrossRefPubMed
25.
Yasueda S, Yamakawa K, Nakanishi Y, Kinoshita M, Kakehi K. Decreased mucin concentrations in tear fluids of contact lens wearers. J Pharm Biomed Anal. 2005;39:187–95.CrossRefPubMed
26.
Nakamura Y, Yokoi N, Tokushige H, Kinoshita S. Sialic acid in human tear fluid decreases in dry eye. Jpn J Ophthalmol. 2004;48:519–23.CrossRefPubMed
27.
Kinoshita S, Kiorpes TC, Friend J, Thoft RA. Goblet cell density in ocular surface disease: a better indicator than tear mucin. Arch Ophthalmol. 1983;101:1284–7.CrossRefPubMed
28.
Ralph RA. Conjunctival goblet cell density in normal subjects and in dry eye syndromes. Invest Ophthalmol. 1975;14:299–302.PubMed
29.
Corrales RM, de Paiva CS, Li DQ, Farley WJ, Henriksson JT, Bergmanson JP, et al. Entrapment of conjunctival goblet cells by desiccation-induced cornification. Invest Ophthalmol Vis Sci. 2011;52:3492–9.PubMedCentralCrossRefPubMed
30.
Argueso P, Balaram M, Spurr-Michaud S, Keutmann HT, Dana MR, Gipson IK. Decreased levels of the goblet cell mucin MUC5AC in tears of patients with Sjogren syndrome. Invest Ophthalmol Vis Sci. 2002;43:1004–11.PubMed
31.
Danjo Y, Watanabe H, Tisdale AS, George M, Tsumura T, Abelson MB, et al. Alteration of mucin in human conjunctival epithelia in dry eye. Invest Ophthalmol Vis Sci. 1998;39:2602–9.PubMed
32.
Gipson IK, Hori Y, Argueso P. Character of ocular surface mucins and their alteration in dry eye disease. Ocul Surf. 2004;2:131–48.CrossRefPubMed
Metadata
Title
Diquafosol sodium ophthalmic solution for the treatment of dry eye: clinical evaluation and biochemical analysis of tear composition
Authors
Chika Shigeyasu
Masakazu Yamada
Yoko Akune
Kazuo Tsubota
Publication date
01-11-2015
Publisher
Springer Japan
Published in
Japanese Journal of Ophthalmology / Issue 6/2015
Print ISSN: 0021-5155
Electronic ISSN: 1613-2246
DOI
https://doi.org/10.1007/s10384-015-0408-y

Other articles of this Issue 6/2015

Japanese Journal of Ophthalmology 6/2015 Go to the issue

Clinical Investigation

Vitreous cysts in patients with retinitis pigmentosa

Erratum

Erratum to: Comparison of microincision vitrectomy and conventional 20-gauge vitrectomy for severe proliferative diabetic retinopathy

Clinical Investigation

Prevalence of and factors associated with myopia in primary school students in the Chaoyang District of Beijing, China

Clinical Investigation

Predictive factors for recurrence of macular edema after successful intravitreal bevacizumab therapy in branch retinal vein occlusion

Clinical Investigation

Changes of orbital tissue volumes and proptosis in patients with thyroid extraocular muscle swelling after methylprednisolone pulse therapy

Scientific Reviewers

Scientific Reviewers